Innovent Biologics, Inc.: Overweight trials

The registry lists 10 Overweight studies with Innovent Biologics, Inc. as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 1 7Phase 2 1Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of IBI3046 in Participants With Overweight or ObesityRecruitingNCT07809945Phase 1
• IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsRecruitingNCT07793019Phase 1
• Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese ParticipantsNot yet recruitingNCT07765160Phase 1
• Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityRecruitingNCT07469800Phase 3
• A Study of IBI3032 in Chinese Participants With Overweight or ObesityActive, not recruitingNCT07170319Phase 1
• A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）Active, not recruitingNCT06884293Phase 3
• A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese SubjectsCompletedNCT05815680Phase 1
• A Study of IBI362 in Participants With Obesity or OverweightCompletedNCT05607680Phase 3
• Clinical Study of IBI362 in Healthy Chinese Male SubjectsCompletedNCT04773977Phase 1
• Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity SubjectsCompletedNCT04440345Phase 1/2